Annovis Bio, Inc. (ANVS)
| Market Cap | 57.44M -10.8% |
| Revenue (ttm) | n/a |
| Net Income | -51.72M |
| EPS | -1.55 |
| Shares Out | 62.02M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,197,306 |
| Open | 0.8850 |
| Previous Close | 0.8472 |
| Day's Range | 0.8142 - 0.9510 |
| 52-Week Range | 0.6161 - 5.5000 |
| Beta | 1.35 |
| Analysts | Strong Buy |
| Price Target | 10.50 (+1,033.79%) |
| Earnings Date | Nov 13, 2026 |
About ANVS
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company’s lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer’s disease, as well as in open-label phase 3 to treat parkinson’s disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer’s disease an... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for ANVS stock is "Strong Buy." The 12-month stock price target is $10.5, which is an increase of 1,033.79% from the latest price.
News
Annovis Bio reports Q3 EPS (22c), consensus (33c)
“The third quarter marked a shift in our focus from enrolling patients in DUET-AD to executing the trial and preparing for the first data readout and for filing a New…
Annovis Provides Corporate Updates and Reports Third Quarter 2026 Financial Results
MALVERN, Pa., Nov. 13, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing buntanetap, an investigational or...
Annovis Bio Earnings release: Q3 2026
Annovis Bio released its Q3 2026 earnings on November 13, 2026, summarizing the period's financial results.
Annovis Bio Quarterly report: Q3 2026
Annovis Bio has published its Q3 2026 quarterly earnings report on November 13, 2026.
Annovis Bio granted U.S. patent covering crystalline form of buntanetap
Annovis Bio (ANVS) announced that the United States Patent and Trademark Office, or USPTO, has issued U.S. Patent No. 12,780,831, titled “Solid Forms of Posiphen D-Tartrate.” The patent contains eleve...
Annovis Bio Granted U.S. Patent Covering New Crystalline Form of Buntanetap
U.S. Patent No. 12,780,831 covers posiphen (buntanetap) D-tartrate Form B, a highly crystalline dihydrate, together with pharmaceutical compositions and methods of preparation, providing protection th...
Annovis Announces Closing of $21.0 Million Public Offering with 24% Contribution from the Board Chairman
Annovis Chairman of the Board invested $5.0 million as part of the underwritten public offering Company expects cash to fund operations through the pivotal Phase 3 Alzheimer's data readout in March 2...
Annovis Bio 21M share Spot Secondary priced at $1.00
Canaccord is acting as sole book running manager for the offering. The deal priced below last closing price of $1.21.
Annovis Announces Pricing of $21.0 Million Public Offering
MALVERN, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy,...
Annovis Bio announces common stock and warrants offering, no amount given
Annovis Bio (ANVS) announced a proposed underwritten public offering in which it intends to offer and sell (i) shares of its common stock or, in lieu of common stock to…
Annovis Announces Launch of Proposed Public Offering
MALVERN, Pa., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy,...
Annovis Bio receives noncompliance notification from Nasdaq
Annovis Bio (ANVS) announced that it received notice from the NYSE that it is no longer in compliance with the NYSE continued listing standards set forth in Section 802.01B of…
Annovis Bio, Inc. Receives Continued Listing Standard Notice from the NYSE
MALVERN, Pa., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy,...
Annovis to Participate in U.S. Biotech Day 2026 and Pharma Partnering Summit 2026
MALVERN, Pa., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy,...
Annovis to Attend the CTAD 2026 with Three Presentations
MALVERN, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy,...
Annovis Bio Proxy statement: Proxy filing
Annovis Bio filed a proxy statement on October 7, 2026, providing details for shareholder voting and corporate governance matters.
Annovis Bio Slides: Corporate presentation
Annovis Bio has posted slides in relation to its latest quarterly earnings report, which was published on October 2, 2026.
Annovis Bio announces partnership with Weave Bio
Annovis Bio (ANVS) announced a collaboration with Weave Bio, an AI platform for regulatory content and knowledge management, in support of the planned New Drug Application, NDA, for buntanetap. Under…
Annovis Announces Partnership with Weave Bio, AI Regulatory Platform, in Preparation of NDA for Buntanetap in Alzheimer's Disease
MALVERN, Pa., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy...
Annovis Bio Proxy statement: Proxy filing
Annovis Bio filed a proxy statement on September 11, 2026, providing details for shareholder voting and corporate governance matters.
Annovis Bio Transcript: Investor update
Pivotal phase III Alzheimer's trial is fully enrolled, with top-line data expected in March and NDA filing to follow. Additional funding is required to continue operations, with management and insiders planning to participate in the raise. Disease-modifying data in 2028 could unlock significant market opportunities.
Annovis Bio price target lowered to $7 from $8 at Roth Capital
Roth Capital analyst Boobalan Pachaiyappa lowered the firm’s price target on Annovis Bio (ANVS) to $7 from $8 and keeps a Buy rating on the shares. Pressure is disproportionately building…
Annovis to Host Corporate Update Webinar on September 2, 2026
MALVERN, Pa., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy,...
Annovis Bio Proxy statement: Proxy filing
Annovis Bio filed a proxy statement on August 25, 2026, providing details for shareholder voting and corporate governance matters.
Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results
MALVERN, Pa., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy,...